Jacqueline Garcia, MD
Hematology & Oncology · Boston, MANPI 1922260934
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $59,161 of the $69,634 with a category attached, or 85.0%. 16 manufacturers reported payments, led by AbbVie at 51.2% of the total. 2025 is the largest year on record at $17,261, 2.6 times the $6,671 reported in 2019.
Across 73 payments — averaging $953.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$36K
- Geron Corporation$7K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- AstraZeneca$4K
- Servier Pharmaceuticals LLC$4K
- Syndax Pharmaceuticals, Inc.$3K
- plus $8K from 10 others
Across 344 payments — averaging $39,228 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$12.6M
- Genentech, Inc.$483K
- Pfizer$266K
- Eli Lilly$106K
- Acerta Pharma LLC$63K
- F. Hoffmann-la Roche AG$23K
What the payments were for
- Consulting fees$59,16185%
- Speaking & faculty fees$5,3488%
- Travel & lodging$2,9424%
- Food & beverage$2,1843%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $35,647 |
| Geron Corporation | 5 | $7,327 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $7,260 |
| AstraZeneca | 2 | $4,235 |
| Servier Pharmaceuticals LLC | 2 | $3,895 |
| Syndax Pharmaceuticals, Inc. | 3 | $2,892 |
| Astellas Pharma Global Development | 1 | $2,300 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,076 |
| Genentech USA, Inc. | 3 | $1,948 |
| Bristol Myers Squibb | 4 | $1,081 |
| F. Hoffmann-la Roche AG | 2 | $393 |
| Stemline Therapeutics Inc. | 1 | $216 |
| Abbott | 1 | $178 |
| Adaptive Biotechnologies Corporation | 1 | $97 |
| Gilead | 1 | $70 |
| Johnson & Johnson Vision Care, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,634 in reported general payments places this provider in the 85th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OjjaaraMomelotinib Dihydrochloride | 49 | $1,334,325 |
| JakafiRuxolitinib Phosphate | 28 | $446,742 |
| VonjoPacritinib Citrate | 14 | $245,664 |
| VenclextaVenetoclax | 34 | $230,819 |
| Imatinib Mesylate | 14 | $25,677 |
| Acyclovir | 51 | $790 |
| ValacyclovirValacyclovir Hcl | 15 | $337 |
| Nystatin | 11 | $326 |
| Allopurinol | 31 | $269 |
| Furosemide | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $35,647 | $230,81934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.